Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
Brain-derived neurotrophic factor (BDNF) activates the receptor tropomyosin-related kinase B (TrkB) with high potency and specificity, promoting neuronal survival, differentiation, and synaptic function. Correlations between altered BDNF expression and/or function and mechanism(s) underlying numerous neurodegenerative conditions, including Alzheimer disease and traumatic brain injury, suggest that TrkB agonists might have therapeutic potential. Using in silico screening with a BDNF loop-domain pharmacophore, followed by low-throughput in vitro screening in mouse fetal hippocampal neurons, we have efficiently identified small molecules with nanomolar neurotrophic activity specific to TrkB versus other Trk family members. Neurotrophic activity was dependent on TrkB and its downstream targets, although compound-induced signaling activation kinetics differed from those triggered by BDNF. A selected prototype compound demonstrated binding specificity to the extracellular domain of TrkB. In in vitro models of neurodegenerative disease, it prevented neuronal degeneration with efficacy equal to that of BDNF, and when administered in vivo, it caused hippocampal and striatal TrkB activation in mice and improved motor learning after traumatic brain injury in rats. These studies demonstrate the utility of loop modeling in drug discovery and reveal what we believe to be the first reported small molecules derived from a targeted BDNF domain that specifically activate TrkB.We propose that these compounds constitute a novel group of tools for the study of TrkB signaling and may provide leads for developing new therapeutic agents for neurodegenerative diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“LM22A-4 was designed to mimic the loop II domain of BDNF and proven to be a partial agonist.”
From Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression (2018) · cites this paper as Massa et al. 2010
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In vitro work showed that LM22A-4 has neuroprotective properties (Massa et al. 2010).”
From Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression (2018) · cites this paper as Massa et al. 2010
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
The molecular neurobiology of depression
Krishnan, V., & Nestler, E. J. (2008) · Nature · doi:10.1038/nature07455 · Cited by 2,889
Trk Receptors: Roles in Neuronal Signal Transduction
Huang, E. J., & Reichardt, L. F. (2003) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.72.121801.161629 · Cited by 2,537
Neurotrophins and their receptors: A convergence point for many signalling pathways
Chao, M. V. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1078 · Cited by 2,298
Neurotrophin signal transduction in the nervous system
Kaplan, D. R., & Miller, F. D. (2000) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(00)00092-1 · Cited by 1,944
Virtual screening of chemical libraries
Shoichet, B. K. (2004) · Nature · doi:10.1038/nature03197 · Cited by 1,425
Ageing and neuronal vulnerability
Mattson, M. P., & Magnus, T. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1886 · Cited by 957
Sairanen, M., Lucas, G., Ernfors, P., Castrén, M., & Castrén, E. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3741-04.2005 · Cited by 763
TrkB Regulates Hippocampal Neurogenesis and Governs Sensitivity to Antidepressive Treatment
Li, Y., Luikart, B. W., Birnbaum, S., Chen, J., Kwon, C.-H., Kernie, S. G., Bassel-Duby, R., & Parada, L. F. (2008) · Neuron · doi:10.1016/j.neuron.2008.06.023 · Cited by 634
Poduslo, J. F., & Curran, G. L. (1996) · Molecular Brain Research · doi:10.1016/0169-328x(95)00250-v · Cited by 614
Research works printed but not linked: 1
- Conte, 2008, Restor Neurol Neurosci., 26, 45
Cited by
Items 101–200 of 403
Neuroregenerative Mechanisms of Allopregnanolone in Alzheimer’s Disease
Irwin, R. W., Wang, J. M., Chen, S., & Brinton, R. D. (2012) · Frontiers in Endocrinology · doi:10.3389/fendo.2011.00117 · Cited by 56
“REVIEW ARTICLE published: 12 January 2012 doi: 10.3389/fendo.2011.00117”
InfluentialKron, M., Lang, M., Adams, I. T., Sceniak, M., Longo, F., & Katz, D. M. (2014) · Disease Models & Mechanisms · doi:10.1242/dmm.016030 · Cited by 59
“…but not all, models in vivo and in vitro (Kajiya et al., 2014; Massa et al., 2010; Han et al., 2012; Schmid et al., D is ea se M od el s & M ec ha ni sm s 2012; Todd et al., 2014), the range of actions of LM22A-4 is quantitatively and qualitatively distinct from that of BDNF (Massa et al., 2010).”
InfluentialSelf-citationLi, W., Bellot-Saez, A., Phillips, M. L., Yang, T., Longo, F. M., & Pozzo-Miller, L. (2017) · Disease Models & Mechanisms · doi:10.1242/dmm.029959 · Cited by 60
“001) and not in WT slices (WT control and LM22A-4, n=16 each), which is consistent with the actions of a partial agonist (Massa et al., 2010).”
BackgroundResultInfluentialSelf-citationNeuroprotective Effects of Physical Activity via the Adaptation of Astrocytes
Maugeri, G., D’Agata, V., Magrì, B., Roggio, F., Castorina, A., Ravalli, S., Rosa, M. D., & Musumeci, G. (2021) · Cells · doi:10.3390/cells10061542 · Cited by 63
“Additionally, BDNF prevents neuronal apoptosis by inducing the expression of the antiapoptotic Bcl-2 family members and by inhibiting proapoptotic proteins such as Bax and Bad [31].”
BackgroundUnlocking Alzheimer’s Disease: The Role of BDNF Signaling in Neuropathology and Treatment
Alqahtani, S. M., Al-Kuraishy, H. M., Al-Gareeb, A. I., Albuhadily, A. K., Alexiou, A. T., Papadakis, M., Hemeda, L. R., Faheem, S. A., & Batiha, G. E. (2025) · NeuroMolecular Medicine · doi:10.1007/s12017-025-08857-x · Cited by 59
“Interest-ingly, LM22a-4, a small molecule mimicking BDNF, has 85% similarity with BDNF and improves hippocampus neuron survival, while preventing neuronal death in AD models (Massa et al., 2010).”
Brain-Derived Neurotrophic Factor: the Link Between Amyloid-β and Memory Loss
Fahnestock, M. (2011) · Future Neurology · doi:10.2217/fnl.11.44 · Cited by 55
Traumatic brain injury: recent advances in plasticity and regeneration
Werner, J. K., & Stevens, R. D. (2015) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000265 · Cited by 67
Ghosh, S., Durgvanshi, S., Agarwal, S., Raghunath, M., & Sinha, J. K. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200429011823 · Cited by 58
“LM22A-4 has shown similar neuroprotective effects, such as activating synapse functioning pathways (AKT and CREB) [82, 83].”
Metabolic Reserve as a Determinant of Cognitive Aging
Stranahan, A. M., & Mattson, M. P. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110899 · Cited by 53
“Data from studies of human subjects and animal models have led not only to clinical trials of neurotrophin delivered directly into the brain, but also to the preclinical development of low molecular weight agents that induce the expression of neurotrophins or activate neurotrophin receptors and exhibit beneficial effe…”
Yang, X., Zhang, M., Xie, B., Peng, Z., Manning, J. R., Zimmerman, R., Wang, Q., Wei, A., Khalifa, M., Reynolds, M. J., et al. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac096 · Cited by 58
Lu, C., Wei, Y., Hu, R., Wang, Y., Li, K., & Li, X. (2015) · Neuromodulation Technology at the Neural Interface · doi:10.1111/ner.12302 · Cited by 59
“It is known that BDNF promote neuronal survival (27), partially via a mechanism involved in antioxidative stress (28,29), which may contribute to the observed effects of tDCS in this study.”
BackgroundZhang, R., Peng, Z., Wang, H., Xue, F., Chen, Y., Wang, Y., Wang, H., & Tan, Q. (2013) · Neurochemical Research · doi:10.1007/s11064-013-1203-0 · Cited by 57
“The ERKs play an important role in the regulation of BDNF [34], and the reduction of ERKs phosphorylation may play a pathological role in depression [35].”
BackgroundSzobota, S., Mathur, P. D., Siegel, S., Black, K., Saragovi, H. U., & Foster, A. C. (2019) · PLoS ONE · doi:10.1371/journal.pone.0224022 · Cited by 60
“The small molecules 7,8-DHF and LM22A4, reported TrkB agonists [20, 24, 25], also did not elicit a phospho-ERK response when applied to TrkB-expressing cells, at doses ranging from 0.”
BackgroundResultTurovskaya, M. V., Gaidin, S. G., Vedunova, M. V., Babaev, A. A., & Turovsky, E. A. (2020) · Neuroscience Bulletin · doi:10.1007/s12264-020-00480-z · Cited by 57
Neurotrophin receptor agonists and antagonists as therapeutic agents: An evolving paradigm
Josephy-Hernandez, S., Jmaeff, S., Pirvulescu, I., Aboulkassim, T., & Saragovi, H. U. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.08.004 · Cited by 54
“TrkB 7,8-DHF Deoxygedunin BDNF Huntington's TrkB 7,8-DHF LM22A-4 Amitriptyline BDNF Riluzole: increased BDNF and transforming growth factor beta-1, and improved symptoms.”
InfluentialTrkB transmembrane domain: bridging structural understanding with therapeutic strategy
Enkavi, G., Girych, M., Moliner, R., Vattulainen, I., & Castrén, E. (2024) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2024.02.001 · Cited by 44
Wang, J., Chen, Y., Yang, Y., Xiao, X., Chen, S., Zhang, C., Jacobs, B., Zhao, B., Bihl, J. C., & Chen, Y. (2016) · Molecular Brain · doi:10.1186/s13041-016-0193-7 · Cited by 54
“The PI3K is the downstream pathway molecule of VEGFR2 and TrkB, which mediates various cell activities includes cell survival, cell proliferation [29-32].”
BackgroundKimura, A. K., Namekata, K., Guo, X., Noro, T., Harada, C., & Harada, T. (2014) · American Journal Of Pathology · doi:10.1016/j.ajpath.2014.11.005 · Cited by 57
“Recently, several selective TrkB agonists have been proposed as therapeutic agents for neurodegenerative diseases.(44,45) Based on the evidence that neurotrophic factors protect the retina from various pathological conditions,(46) development of such compounds that mimic some of the beneficial effects of neurotrophic…”
BackgroundUluç, K., Kendigelen, P., Fidan, E., Zhang, L., Chanana, V., Kintner, D. B., Aktüre, E., Song, C., Ye, K., Sun, D., et al. (2013) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/18715273113129990061 · Cited by 56
“Efforts have been made to find non-peptide, small molecule ligands capable of activating TrkB signaling with a high potency, specificity and better bioavailability [16, 17].”
BackgroundLoss of MeCP2 disrupts cell autonomous and autocrine BDNF signaling in mouse glutamatergic neurons
Sampathkumar, C., Wu, Y.-J., Vadhvani, M., Trimbuch, T., Eickholt, B., & Rosenmund, C. (2016) · eLife · doi:10.7554/elife.19374 · Cited by 52
“That BDNF is a neurotrophin with poor blood-brain barrier penetration characteristics (Poduslo and Curran, 1996) prompted the need for small molecule substitutes that act as TrkB agonists and activate TrkB signaling (Jang et al., 2010; Massa et al., 2010).”
BackgroundBrain-Derived Neurotrophic Factor and Rett Syndrome
Katz, D. M. (2014) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-45106-5_18 · Cited by 56
“In the first test of a BDNF-targeted therapeutic strategy, Ogier et al. (2007) examined whether or not pharmacologic elevation of endogenous BDNF expression with ampakine drugs could improve respiratory function inMecp2 null mice.”
BackgroundTherapeutic potential of a TrkB agonistic antibody for Alzheimer's disease
Wang, S., Yao, H., Xu, Y., Hao, R., Zhang, W., Liu, H., Huang, Y., Guo, W., & Lu, B. (2020) · Theranostics · doi:10.7150/thno.44165 · Cited by 53
“Efforts have been made to develop a small molecule activator for TrkB [62-66].”
BackgroundNeurotrophin-targeted therapeutics: A gateway to cognition and more?
Nordvall, G., Forsell, P., & Sandin, J. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.07.003 · Cited by 48
Shimizu, A., Mitani, T., Tanaka, S., Fujii, H., Maebuchi, M., Amiya, Y., Tanaka, M., Matsui, T., Nakamura, S., & Katayama, S. (2018) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.8b01581 · Cited by 52
Gaidin, S. G., Turovskaya, M. V., Gavrish, M. S., Babaev, A. A., Mal’tseva, V. N., Блинова, Е. В., & Turovsky, E. A. (2019) · International Journal of Neuroscience · doi:10.1080/00207454.2019.1691205 · Cited by 52
“BDNF binds with TrkB receptor with high affinity [13]”
BackgroundFletcher, J. L., Dill, L. K., Wood, R. J., Wang, S., Robertson, K., Murray, S. S., Zamani, A., & Semple, B. D. (2021) · Experimental Neurology · doi:10.1016/j.expneurol.2021.113652 · Cited by 52
Dailah, H. G. (2022) · Molecules · doi:10.3390/molecules27217207 · Cited by 56
Design and synthesis of dipeptide mimetics of the brain-derived neurotrophic factor
Гудашева, Т. А., Тарасюк, А. В., Помогайбо, С. В., Логвинов, И. О., Povarnina, P. Y., Антипова, Т. А., & Середенин, С. Б. (2012) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162012030053 · Cited by 54
Targeting reactive astrogliosis by novel biotechnological strategies
Colangelo, A. M., Cirillo, G., Lavitrano, M., Alberghina, L., & Papa, M. (2011) · Biotechnology Advances · doi:10.1016/j.biotechadv.2011.06.016 · Cited by 53
Cirillo, G., Colangelo, A. M., Bianco, M. R., Cavaliere, C., Zaccaro, L., Sarmientos, P., Alberghina, L., & Papa, M. (2011) · Biotechnology Advances · doi:10.1016/j.biotechadv.2011.05.008 · Cited by 50
Copper, BDNF and Its N‐terminal Domain: Inorganic Features and Biological Perspectives
Travaglia, A., La Mendola, D., Magrì, A., Nicoletti, V. G., Pietropaolo, A., & Rizzarelli, E. (2012) · Chemistry – A European Journal · doi:10.1002/chem.201202775 · Cited by 43
The role of growth factors as a therapeutic approach to demyelinating disease
Huang, Y., & Dreyfus, C. F. (2016) · Experimental Neurology · doi:10.1016/j.expneurol.2016.02.023 · Cited by 47
“In these cases small molecules were developed that mimic a region of BDNF that binds to its receptor, trkB (Massa et al 2010, Wong et al 2014).”
BackgroundPediaditakis, I., Efstathopoulos, P., Prousis, K. C., Zervoú, M., Arévalo, J. C., Alexaki, V. I., Nikoletopoulou, V., Karagianni, E., Potamitis, C., Tavernarakis, N., et al. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.09.007 · Cited by 46
“Recently, TrkA and TrkB low affinity agonists (compounds MT2 and LM22A respectively) have also been reported, using in silico screening, to specifically activate these receptors (Scarpi et al., 2012; Massa et al., 2010).”
RNA Aptamer-Based Functional Ligands of the Neurotrophin Receptor, TrkB
Huang, Y. Z., Hernández, F. J., Gu, B., Stockdale, K. R., Nanapaneni, K., Scheetz, T. E., Behlke, M. A., Peek, A. S., Bair, T., Giangrande, P. H., et al. (2012) · Molecular Pharmacology · doi:10.1124/mol.112.078220 · Cited by 48
“, 2006), and diverse small molecules (Jang et al., 2010; Massa et al., 2010), these reagents seem to be full agonists and thus may have the same drawbacks as BDNF.”
BackgroundSanchez, M. M., Das, D., Taylor, J. L., Noda, A., Yesavage, J. A., & Salehi, A. (2011) · Translational Psychiatry · doi:10.1038/tp.2011.47 · Cited by 45
Lin, T., Chang, K., Chiu, Y., Weng, Z.-K., Sun, Y., Lin, W., Lee‐Chen, G., & Chen, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112734 · Cited by 51
“However, the limited ability for crossing the BBB restricts the application of LM22A-4 in treating neurodegenerative diseases [44].”
BackgroundRett Syndrome: Reaching for Clinical Trials
Pozzo‐Miller, L. D., Pati, S. B. B., & Percy, A. K. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0353-y · Cited by 47
Scheuing, L., Chiu, C., Liao, H., Linares, G. R., & Chuang, D. (2014) · International Journal of Biological Sciences · doi:10.7150/ijbs.9898 · Cited by 47
“BBB permeable TrkB agonists [95] should increase BDNF downstream effectors within the brain and also provide increased neuroprotection.”
BackgroundLi, Q., Wang, P., Huang, C., Chen, B., Liu, J., Zhao, M., & Zhao, J. (2019) · Journal of Molecular Neuroscience · doi:10.1007/s12031-019-01263-6 · Cited by 45
Liu, Y., Yang, J., Che, X., Huang, J., Zhang, X., Fu, X., Cai, J., Yao, Y., Zhang, H., Cai, R., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2109600118 · Cited by 45
Regulatory role of NGFs in neurocognitive functions
Kumar, A., Pareek, V., Faiq, M. A., Kumar, P., Raza, K., Prasoon, P., Dantham, S., & Mochan, S. (2017) · Reviews in the Neurosciences · doi:10.1515/revneuro-2016-0031 · Cited by 47
Yang, T., Massa, S. M., Tran, K. C., Simmons, D. A., Rajadas, J., Zeng, A. Y., Jang, T., Carsanaro, S., & Longo, F. M. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.06.015 · Cited by 47
Self-citationPankiewicz, P., Szybiński, M., Kisielewska, K., Gołębiowski, F., Krzemiński, P., Rutkowska-Włodarczyk, I., Moszczyński-Pętkowski, R., Gurba-Bryśkiewicz, L., Delis, M., Mulewski, K., et al. (2021) · Pharmaceuticals · doi:10.3390/ph14080704 · Cited by 42
Shin, M., Kim, H. G., Baek, S. H., Jung, W.-R., Park, D. I., Park, J., Jo, D., & Kim, K.-L. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.10.091 · Cited by 43
“Moreover, smallmolecule BDNF receptor agonists such as LM22A or 7,8- dihydroxyflavone have shown neuroprotective effects against in vitro or in vivo AD models, respectively (Devi and Ohno, 2012; Massa et al., 2010).”
Modulating Neurotrophin Receptor Signaling as a Therapeutic Strategy for Huntington’s Disease
Simmons, D. A. (2017) · Journal of Huntington s Disease · doi:10.3233/jhd-170275 · Cited by 43
“For example, to detect LM22A-4 activation of TrkB (Y490) in hippocampal neurons by Western blotting 8–11 replications were performed from 4-5 independent cultures [187].”
MethodHypothesis‐driven investigations of diverse pharmacological targets in two mouse models of autism
Rhine, M. A., Parrott, J. M., Schultz, M. N., Kazdoba, T. M., & Crawley, J. N. (2019) · Autism Research · doi:10.1002/aur.2066 · Cited by 47
“BDNF regulates neuronal growth and differentiation, synaptic plasticity, learning and memory, and is implicated in mood disorders and responses to aversive social experiences [Berton et al., 2006; Björkholm & Monteggia, 2016; Mitre, Mariga, & Chao, 2017; Rosas-Vidal et al., 2018].”
BackgroundInfluentialNANOCI—Nanotechnology Based Cochlear Implant With Gapless Interface to Auditory Neurons
Senn, P., Roccio, M., Hahnewald, S., Frick, C., Kwiatkowska, M., Ishikawa, M., Bakó, P., Li, H., Edin, F., Liu, W., et al. (2017) · Otology & Neurotology · doi:10.1097/mao.0000000000001439 · Cited by 42
“and their effects on the inner ear neurons are as yet unknown (13).”
BackgroundSpencer, A. P., Torrado, M., Custódio, B., Silva-Reis, S. C., Santos, S. D., Leiro, V., & Pêgo, A. P. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12020192 · Cited by 46
Wei, L., Kan, L.-Y., Zeng, H.-Y., Tang, Y.-Y., Huang, H., Xie, M., Zou, W., Wang, C., Zhang, P., & Tang, X. (2018) · NeuroMolecular Medicine · doi:10.1007/s12017-018-8489-7 · Cited by 40
Yang, T., Tran, K. C., Zeng, A. Y., Massa, S. M., & Longo, F. M. (2020) · Scientific Reports · doi:10.1038/s41598-020-77210-y · Cited by 41
Self-citationWiciński, M., Malinowski, B., Węclewicz, M. M., Grześk, E., & Grześk, G. (2017) · BioMed Research International · doi:10.1155/2017/9202954 · Cited by 44
Nguyen, H. T. H., Wood, R. J., Prawdiuk, A. R., Furness, S. G. B., Xiao, J., Murray, S. S., & Fletcher, J. L. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00205 · Cited by 38
Wong, A. W., Giuffrida, L., Wood, R., Peckham, H., Gonsalvez, D., Murray, S. S., Hughes, R. A., & Xiao, J. (2014) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2014.10.002 · Cited by 39
Neurotrophins and Their Receptors: BDNF’s Role in GABAergic Neurodevelopment and Disease
Caño, C. H.-D., Varela-Andrés, N., Cebrián-León, A., & Deogracias, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158312 · Cited by 41
“Pharmacological approaches that enhance BDNF-dependent signaling have shown promise as therapy for RTT. TrkB agonists like LM22A-4 [159] and 7,8-DHF [160] have been able to revert some RTT symptoms in animal models, including restoration of hippocampal synaptic plasticity and object location memory…”
BackgroundLi, W.-Y., Zhu, Q., Jin, L.-Y., Yang, Y., Xu, X.-Y., & Hu, X.-Y. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.308665 · Cited by 39
“The PI3K/ AKT pathway is downstream of TrkB, which mediates several cellular activities, including cell survival and proliferation (Holmes et al., 2007; Massa et al., 2010).”
BackgroundNovel small molecule activators of the Trk family of receptor tyrosine kinases
Obianyo, O., & Ye, K. (2013) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2012.08.021 · Cited by 39
“One of the compounds, LM22A-4, lacking any peptide bonds, was found to selectively associate with the TrkB receptor and induce its autophosphorylation as well as the phosphorylation of its downstream signaling proteins, Akt and Erk (37).”
BackgroundInfluentialNie, S., Ma, K., Sun, M., Lee, M., Yang, T., Chen, G., Zhang, Z., Zhang, Z., & Cao, X. (2019) · Parkinson s Disease · doi:10.1155/2019/9193534 · Cited by 41
Self-citationVitamin-D-Free Regimen Intensifies the Spatial Learning Deficit in Alzheimer's Disease
Taghizadeh, M., Djazayery, A., Salami, M., Eshraghian, M. R., & Talaei, S. A. (2011) · International Journal of Neuroscience · doi:10.3109/00207454.2010.523132 · Cited by 41
“Neurotrophins are secreted proteins that support the survival, differentiation of neurons, synaptic function, and function in the adult and aging brain (Massa et al., 2010; Siegel & Chauhan, 2000; Woo & Lu, 2006).”
BackgroundGu, F., Parada, I., Yang, T., Longo, F. M., & Prince, D. A. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.01.018 · Cited by 40
Self-citationRon, D., & Berger, A. L. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4882-z · Cited by 40
“Using in vitro assays in hippocampal neurons, LM22A-4 was shown to activate TrkB signaling (Massa et al. 2010), and the compound was shown to exhibit beneficial effects in animal models of Rett syndrome, Huntington’s disease (Schmid et al.”
Neuroregeneration in Parkinson’s Disease: From Proteins to Small Molecules
Sidorova, Y. A., Volcho, K. P., & Salakhutdinov, N. F. (2018) · Current Neuropharmacology · doi:10.2174/1570159x16666180905094123 · Cited by 40
Gu, F., Parada, I., Shen, F., Li, J., Bacci, A., Graber, K., Taghavi, R. M. M., Scalise, K., Schwartzkroin, P. A., Wenzel, J., et al. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.08.008 · Cited by 38
Therapeutic Targeting Strategies for Early- to Late-Staged Alzheimer’s Disease
Kang, Y. J., Diep, Y. N., Tran, M., & Cho, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249591 · Cited by 36
“Other examples involve deoxygedunin [67], LM22A-4 [68], and bicyclic BDNF loop mimetics [248] that have proven their BDNF neurotrophic effects in AD.”
BackgroundDaly, C., Shine, L., Heffernan, T., Deeti, S., Reynolds, A., O'Connor, J. J., Dillon, E., Duffy, D. J., Kölch, W., Cagney, G., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-11513-5 · Cited by 38
Xu, F., Lv, C., Deng, Y., Liu, Y., Gong, Q., Shi, J., & Gao, J. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00523 · Cited by 38
“BDNF phosphorylates TrkB at tyrosine 816 site (Bathina and Das, 2015), once it is phosphorylated exerts multiple neuroprotective effects promoting neuroplasticity, neurogenesis, and angiogenesis (Massa et al., 2010; Schmid et al., 2012), which are related with learning and memory recovery.”
BackgroundSelf-citationStatus of precision medicine approaches to traumatic brain injury
Reddi, S., Thakker‐Varia, S., Alder, J., & Giarratana, A. O. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.335824 · Cited by 39
“One method uses BDNF mimics that act as trkB agonists in order to stimulate mature BDNF signaling (Massa et al., 2010).”
MethodAre immunotherapies for Huntington’s disease a realistic option?
Denis, H. L., Lauruol, F., & Cicchetti, F. (2018) · Molecular Psychiatry · doi:10.1038/s41380-018-0021-9 · Cited by 38
“However, URB597 is currently in clinical trials for schizophrenia (NCT00916201), so could in theory be easily moved to trials in HD. Tropomyosin receptor kinase B (TrkB) ligand: LM22A-4 TrkB is the main receptor of BDNF, which is involved in neuronal/glial development and survival.”
BackgroundInfluentialAnti-aging activity and their mechanisms of natural food-derived peptides: current advancements
Li, J., Wang, J., Zhang, N., Li, Y., Cai, Z., Li, G., Liu, Z., Liu, Z., Wang, Y., Shao, X., et al. (2023) · Food Innovation and Advances · doi:10.48130/fia-2023-0028 · Cited by 37
In Vivo AAV1 Transduction With hRheb(S16H) Protects Hippocampal Neurons by BDNF Production
Jeon, M., Nam, J. H., Shin, W.-H., Leem, E., Jeong, K. H., Jung, U. J., Bae, Y., Jin, Y., Kholodilov, N. G., Burke, R. E., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.241 · Cited by 35
Dahlström, M., Madjid, N., Nordvall, G., Halldin, M. M., Vazquez-Juarez, E., Lindskog, M., Sandin, J., Winblad, B., Eriksdotter, M., & Forsell, P. (2021) · Cells · doi:10.3390/cells10081871 · Cited by 33
“Several attempts to identify and develop small molecule activators of neurotrophin signaling have been made, including peptidometics [28–35], small molecules with agonistic properties such as 7,8-dihydroxyflavone [36], gambogic amide [37], amitriptyline [38], LM22A [39] AIT-082 [40,41], L-783,281 and its analogues [42…”
BackgroundZheng, M., Zhou, M., Chen, M., Lü, Y., Shi, D., Wang, J., & Liu, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.772485 · Cited by 33
Гудашева, Т. А., Логвинов, И. О., Антипова, Т. А., & Середенин, С. Б. (2013) · Doklady Biochemistry and Biophysics · doi:10.1134/s1607672913040121 · Cited by 33
Differential effect of clopidogrel and aspirin on the release of BDNF from platelets
Stoll, P., Plessow, A., Bratke, K., Virchow, J. C., Jr., & Lommatzsch, M. (2011) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2011.06.015 · Cited by 33
“It has been shown in several animal models of experimental focal cerebral ischemia that systemic or local application of BDNF significantly improves the recovery of neuronal function after injury (Schabitz et al., 2007; Ploughman et al., 2009; Massa et al., 2010; Jiang et al., 2011).”
BackgroundInfluentialBernard‐Gauthier, V., Aliaga, A., Aliaga, A., Boudjemeline, M., Hopewell, R., Kostikov, A. P., Rosa‐Neto, P., Thiel, A., & Schirrmacher, R. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn500193f · Cited by 33
Boakye, P. A., Rančić, V., Whitlock, K., Simmons, D. A., Longo, F. M., Ballanyi, K., & Smith, P. A. (2019) · Journal of Neurophysiology · doi:10.1152/jn.00839.2018 · Cited by 34
“Because CSF-1 receptors seem to be absent from dorsal horn neurons (Chitu et al. 2016), it is likely that CSF-1 releases GAD67EGFP Neuron Putative Excitatory Delay Neuron sEPSC Frequency sEPSC Amplitude sEPSC Frequency sEPSC Amplitude CSF-1 sEPSC Frequency Trk B CSF-1R Receptor for yet to be identified mediator Microg…”
BackgroundMethodSelf-citationYang, T., Liu, H., Tran, K. C., Leng, A., Massa, S. M., & Longo, F. M. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01034-0 · Cited by 33
Self-citationBurnouf, T., Kuo, Y., Blum, D., Burnouf, S., & Su, C. (2011) · Transfusion · doi:10.1111/j.1537-2995.2011.03494.x · Cited by 37
“In line, increasing BDNF prevents neuronal degeneration in several neurodegenerative conditions.(1,11) BDNF levels correlate with behavioral changes in humans and animal models.”
BackgroundKajiya, M., Takeshita, K., Kittaka, M., Matsuda, S., Ouhara, K., Takeda, K., Takata, T., Kitagawa, M., Fujita, T., Shiba, H., et al. (2014) · International Immunopharmacology · doi:10.1016/j.intimp.2014.01.028 · Cited by 38
“Previous studies demonstrated that PI3Kinase–Akt signaling can also be activated by LM22A-4 [26] and its activation is involved in the regulation of OPN expression in osteoblast [29].”
BackgroundAntidepressant Effect of Dimeric Dipeptide GSB-106, an Original Low-Molecular-Weight Mimetic of BDNF
Середенин, С. Б., Воронина, Т. А., Гудашева, Т. А., Гарибова, Т. Л., Молодавкин, Г. М., Литвинова, С. А., Елизарова, О. А., & Посева, В. И. (2013) · Acta Naturae · doi:10.32607/20758251-2013-5-4-105-109 · Cited by 35
A monolayer hiPSC culture system for autophagy/mitophagy studies in human dopaminergic neurons
Stathakos, P., Jiménez-Moreno, N., Crompton, L. A., Nistor, P., Badger, J. L., Barbuti, P. A., Kerrigan, T. L., Randall, A. D., Caldwell, M. A., & Lane, J. D. (2020) · Autophagy · doi:10.1080/15548627.2020.1739441 · Cited by 32
“We omitted EGF (favors glial differentiation [41,42]), and included: purmorphamine (SHH agonist); FGF8/FGF8A; ascorbic acid (AA; improves mDAN survival [43]); BDNF (improves neuronal survival through activation of NTRK2 receptors, and enhances dopamine release/uptake [44,45]); 856 P.”
BackgroundTargets for preventing epilepsy following cortical injury
Li, H., McDonald, W. S., Parada, I., Faria, L. C., Graber, K., Takahashi, D. K., Ma, Y., & Prince, D. A. (2011) · Neuroscience Letters · doi:10.1016/j.neulet.2011.02.042 · Cited by 32
Andiappan, A. K., Parate, P. N., Anantharaman, R., Suri, B. K., Wang, D. Y., & Chew, F. T. (2011) · Cytokine · doi:10.1016/j.cyto.2011.05.008 · Cited by 34
“Several studies have suggested that BDNF has great therapeutic potential to treat a wide variety of neurodegenerative diseases [55,56].”
BackgroundNeuroprotective and restorative effects of the brain-derived neurotrophic factor in retinal diseases
Afarid, M., Nami, M., & Zare, B. (2016) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2016.02.024 · Cited by 32
Prevention of dendritic and synaptic deficits and cognitive impairment with a neurotrophic compound
Baazaoui, N., & Iqbal, K. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0273-7 · Cited by 31
“The rescue of cognitive impairment by P021 treatment found in the present study is consistent with similar beneficial effects shown previously with 7,8-DHF [36, 37] and other BDNF agonist compounds [38, 39].”
ResultBDNF genotype influence the efficacy of rTMS in stroke patients
Uhm, K. E., Kim, Y., Yoon, K. J., Hwang, J. M., & Chang, W. H. (2015) · Neuroscience Letters · doi:10.1016/j.neulet.2015.03.053 · Cited by 30
Growth factors and their peptide mimetics for treatment of traumatic brain injury
Atkinson, E. A., & Dickman, R. (2023) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2023.117368 · Cited by 31
Beyond traditional pharmacology: new tools and approaches
Gurevich, E. V., & Gurevich, V. V. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13066 · Cited by 31
“Allosteric activators of receptor tyrosine kinases seem to be able to induce the receptor dimerization required for full activation (Massa et al., 2010).”
BackgroundГудашева, Т. А., Povarnina, P. Y., Тарасюк, А. В., & Середенин, С. Б. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190329122852 · Cited by 30
Traumatic Brain Injury and Posttraumatic Epilepsy
Prince, D. A., Parada, I., & Graber, K. (2012) · Oxford University Press eBooks · doi:10.1093/med/9780199746545.003.0024 · Cited by 31
Bernard‐Gauthier, V., Bailey, J. J., Mossine, A. V., Lindner, S., Kaiser, L., Aliaga, A., Shao, X., Quesada, C., Sherman, P. S., Mahringer, A., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00396 · Cited by 30
Gonzalez, S., McHugh, T. L. M., Yang, T., Syriani, W., Massa, S. M., Longo, F. M., & Simmons, D. A. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105563 · Cited by 30
Self-citationBak, D. H., Zhang, E., Yi, M., Kim, D. K., Lim, K., Kim, J.-J., & Kim, D. W. (2015) · Scientific Reports · doi:10.1038/srep15465 · Cited by 33
Targeted pharmacological treatment of autism spectrum disorders: fragile X and Rett syndromes
Wang, H., Pati, S. B. B., Pozzo‐Miller, L. D., & Doering, L. C. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00055 · Cited by 34
Zagrebelsky, M., & Körte, M. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.374138 · Cited by 30
“Massa et al., 2010; Schmid et al., 2012; Simmons et al., 2013; Todd et al., 2014 29D7 antibody 1) Binds both mouse and human TrkB, induces phosphorylation; 2) Promotes survival and growth of cortical neurons.”
BackgroundChang, H., Wang, Y.-H., Tung, C., Yeh, C., & Liu, Y. (2016) · Psychiatry Investigation · doi:10.4306/pi.2016.13.5.531 · Cited by 31
Guo, Y., Lu, Y., Zheng, Y., Chen, X., Dong, J., Yuan, R.-R., Huang, S., Yu, H., Wang, Y., Chen, Z.-Y., et al. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.3148-16.2017 · Cited by 30
“BDNF–TrkB signaling pathways have also been demonstrated to improve hippocampus-dependent memory independently of A metabolism (Nagahara et al., 2009; Massa et al., 2010).”
BackgroundDing, Y., Chow, S. H., Chen, J., Brun, A. P. L., Wu, C., Duff, A. P., Wang, Y., Song, J., Wang, J.-H., Wong, V. H. Y., et al. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.03.043 · Cited by 27
Baazaoui, N., & Iqbal, K. (2022) · Biomolecules · doi:10.3390/biom12101409 · Cited by 30
The Emerging Landscape of Small-Molecule Therapeutics for the Treatment of Huntington’s Disease
Ahamad, S., & Bhat, S. A. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00799 · Cited by 33
Antidepressant effect of Stillen™
Jeong, H., Kim, J.-H., Kim, N., Yoou, M., Nam, S., Kim, K.-Y., Choi, Y., Jang, J., Kang, I., Baek, N., et al. (2014) · Archives of Pharmacal Research · doi:10.1007/s12272-014-0472-8 · Cited by 27
“beneficial effect in depressive disorders (Massa et al. 2010).”
BackgroundInfluential
Metadata
- Authors
- Massa, S. M., Yang, T., Xie, Y., Shi, J., Bilgen, M., Joyce, J. N., Nehama, D., Rajadas, J., & Longo, F. M.
- Affiliations
- University of California, San Francisco (US)
- Stanford University (US)
- University of North Carolina at Chapel Hill (US)
- Medical University of South Carolina (US)
- Banner Sun Health Research Institute (US)
- Corresponding author
- Longo, Frank M.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2010-05-03
- Volume
- 120
- Issue
- 5
- Pages
- 1774-1785
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC2860903
- OpenAlex
- W2055583081
- Cited by
- 406
- References
- 64
- Citations by year
- 2026: 6 · 2025: 22 · 2024: 18 · 2023: 25 · 2022: 22 · 2021: 21 · 2020: 42 · 2019: 22 · 2018: 18 · 2017: 26 · 2016: 23 · 2015: 21 · 2014: 40 · 2013: 41 · 2012: 32
- FWCI
- 12.92
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- U.S. Department of Defense (DAMD170310532)
- U.S. Department of Veterans Affairs
- Alzheimer's Association
- Koret Foundation
- Jean Perkins Foundation
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacological Receptor Mechanisms and Effects
- Keywords
- BDNF mimetic, TrkB signaling, brain-derived neurotrophic factor, small molecule agonists, neurotrophic activity, neurodegeneration, traumatic brain injury, Alzheimer's disease, pharmacophore modeling, loop domains, hippocampal neurons, motor learning, neurodegenerative disease therapeutics
- MeSH terms
- Animals, Hippocampus, Kinetics, Male, Mice, Inbred C57BL, Models, Biological, Neurons, Phosphorylation, Protein Binding, Signal Transduction, Rats, Sprague-Dawley, Brain-Derived Neurotrophic Factor, Neurodegenerative Diseases, Receptor, trkB, NIH 3T3 Cells, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.